Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a suspected or confirmed tumour of an endocrine gland — such as the thyroid, parathyroid, adrenal glands, pancreas, or related areas — based on imaging, blood/urine tests, or tissue samples already taken.
- People who have a pre-cancerous or potentially cancerous condition in an endocrine gland where surgery or a biopsy is already part of their planned standard care.
- People who have been referred to an Endocrine specialist team through another study, for assessment of an endocrine condition confirmed through imaging, lab tests, or tissue samples.
- People whose general health and ability to function meet an acceptable level — rated 0 to 2 on a standard medical scale, meaning able to carry out daily activities with at most moderate limitations (confirm with trial site).
- People whose physical health falls within acceptable limits before undergoing a biopsy or surgery, as assessed by standard medical guidelines.
- People who already have surgery or a biopsy planned as part of their treatment — participation is not open solely for the purpose of collecting tissue samples.
- People aged 4 years or older.
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Naris Nilubol, M.D., National Cancer Institute (NCI)
Phone: (240) 858-7033
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To develop a genetic, epigenetic, metabolomic, and proteomic profile of endocrine neoplasm that will allow us to distinguish benign from malignant tumor for each of the endocrine histologies under study.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.